FDA
-
-
-
-
-
-
-
Aldeyra Therapeutics receives FDA extension for dry eye drug review
-
-
-
-
-
-
-
Aldeyra receives European orphan designation for eye cancer drug
-
-
-
-
-
-
-
FDA accepts Aldeyra's reproxalap drug application for dry eye disease
-
-
-
-
-
-
-
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
-
-
-
-
-
-
-
ALDX INQUIRY: BFA Law Notifies Aldeyra Therapeutics, Inc. Investors to Contact the Firm About Pending Investigation into the Company
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
-
322,090 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

